Amarin (AMRN) Stock Price, News, Quotes-Moomoo

Trade Overview

Unit: --

Capital Trend

IntradayDayWeekMonth

No Data

News

Express News | Amarin Published Data In Journal Of The American Heart Association Showing Post-Hoc Analysis Of REDUCE-IT Study Among Statin-Treated Patients With Elevated Triglycerides And High Cardiovascular Risk, VASCEPA/VAZKEPA
BenzingaFeb 27 09:03 ET
Amarin to Report Fourth Quarter and Full Year 2024 Financial Results and Host Conference Call on March 12, 2025
GlobeNewswireFeb 19 08:30 ET
Tariffs Expected to Bring Pharmaceutical Price Bumps, Shortages -- Market Talk
WSJFeb 10 10:43 ET
European Equities Traded in the US as American Depositary Receipts Kick Off Week Higher in Monday Trading
MT NewswiresDec 16, 2024 11:10 ET
Amarin Corporation Announces National Reimbursement Approval for VAZKEPA in Italy to Reduce Cardiovascular Risk in High-Risk Patients
Quiver QuantitativeDec 16, 2024 07:12 ET
Executive Reshuffles: JPM, QCOM, DVN and LTC
Seeking AlphaDec 14, 2024 15:54 ET

Comments

Teddy123

3 hours ago

Amarin Marks Key Milestone for VASCEPA®/VAZKEPA® (Icosapent Ethyl) -- Publication of Post Hoc Analysis of REDUCE-IT in Journal of the American Heart Association Reports Benefit on Top of Cholesterol

$Amarin (AMRN.US)$
Can This Cardiovascular Drug Work Where Others Fall Short? New REDUCE-IT Data Reveals 34% Event Reduction

Jaguar8

3 hours ago

NEWS

$Amarin (AMRN.US)$
Amarin Marks Key Milestone for VASCEPA®/VAZKEPA® (Icosapent Ethyl) -- Publication of Post Hoc Analysis of REDUCE-IT in Journal of the American Heart Association Reports Benefit on Top of Cholesterol Lowering
Thursday, 27th February at 9:00 am
-- Peer-Reviewed Paper Indicates Icosapent Ethyl (IPE) Reduced Composite Cardiovascular Endpoint Events Regardless of Baseline LDL-C Levels; Significantly Reduced Events by 34% Among Patients with Very Well-Controlled Low-Density Lipo...

1

Tonyco

Dec 16, 2024 16:03

$Amarin (AMRN.US)$
undervalued, oversold
C&E: 156M ST Debt: 9.5M, LT Debt: 8.88M CR: 3.2 QR: 2.08 FCF: -18M
The risk of dilution is low for now. However, cash burn is problematic. Expanded to Euro markets w/2039 patent expiry

Jaguar8

Dec 16, 2024 06:03

NEWS

$Amarin (AMRN.US)$
Amarin Receives National Reimbursement for VAZKEPA® in Italy
Monday, 16th December at 7:00 am
-- Italian Health Authorities Approve VAZKEPA® (icosapent ethyl) for National Reimbursement to Reduce Cardiovascular Risk in Eligible High-Risk Patients1 --
-- Italy is the Third EU5 Market to Grant National Reimbursement; Ninth National Reimbursement for VAZKEPA® Overall in Europe --
-- European Progress Has Advanced Patient Access: Countries That Have Provided Access to VAZKEP...

3

Jaguar8

Nov 22, 2024 15:53

NEWS

$Amarin (AMRN.US)$
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing.
On November 22, 2024, Amarin Corporation plc (the “Company”) received a notice (the “Extension Notice”) from the Nasdaq Listing Qualifications Department (the “Staff”) of the Nasdaq Stock Market LLC (“Nasdaq”) informing the Company that Nasdaq has granted the Company an additional 180 calendar days, or until May 19, 2025, to regain compliance with the minimum bid price requi...

1

AMRN Amarin

Trade Overview

Capital Trend

News

Comments

Trending Stocks